Sphingolipid regulation of tissue fibrosis

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 123-129

  Shea, Barry S ^a   Tager, Andrew M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Fibrosis; S1P; Sphingolipids

Indexed keywords

CERAMIDE; DIHYDROSPHINGOSINE 1 PHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMAD2 PROTEIN; SMAD3 PROTEIN; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

COLLAGEN SYNTHESIS; DISEASE ASSOCIATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; FIBROSIS; GENE EXPRESSION REGULATION; HEART MUSCLE FIBROSIS; HUMAN; LIPID METABOLISM; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; OCULAR FIBROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84863899886     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010123     Document Type: Review

References (93)

1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 183(4): 431-40.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117(3): 557-67.
3. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev 2008; 9(2): 139-50.
4. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73: 321-54.
5. Rivera R, Chun J. Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol 2008; 160: 25-46.
6. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010; 62(4): 579-87.
7. Watterson KR, Lanning DA, Diegelmann RF, Spiegel S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen 2007; 15(5):607-16.
8. Garcia JG, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001; 108(5): 689-701.
9. Goparaju SK, Jolly PS, Watterson KR, et al. The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol 2005; 25(10): 4237-49.
10. Keller CD, Rivera Gil P, Tolle M, et al. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 2007; 170(1): 281-92.
11. Hagen N, Van Veldhoven PP, Proia RL, Park H, Merrill AH Jr, van Echten-Deckert G. Subcellular origin of sphingosine 1-phosphate is essential for its toxic effect in lyase-deficient neurons. J Biol Chem 2009; 284(17): 11346-53.
12. Imasawa T, Koike K, Ishii I, Chun J, Yatomi Y. Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells. Biochem Biophys Res Commun 2010; 392(2): 207-11.
13. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 2010; 43(6): 662-73.
14. Bu S, Asano Y, Bujor A, Highland K, Hant F, Trojanowska M. Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum 2010; 62(7): 2117-26.
15. Li C, Jiang X, Yang L, Liu X, Yue S, Li L. Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasisinduced liver fibrosis. Am J Pathol 2009; 175(4): 1464-72.
16. Takuwa N, Ohkura S, Takashima S, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 2010; 85(3): 484-93.
17. Swaney JS, Moreno KM, Gentile AM, Sabbadini RA, Stoller GL. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Exp Eye Res 2008; 87(4): 367-75.
18. Tokumura A, Carbone LD, Yoshioka Y, et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009; 6(4): 168-76.
19. Ikeda H, Ohkawa R, Watanabe N, et al. Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta 2010; 411(9-10): 765-70.
20. Carter HE, Glick FJ, Norris WP, Phillips GE. Biochemistry of the sphingolipides: III. Structure of sphingosine. J Biol Chem 1947; 170(1): 285-94.
21. Pruett ST, Bushnev A, Hagedorn K, et al. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J Lipid Res 2008; 49(8): 1621-39.
22. Brindley DN. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem 2004; 92(5): 900-12.
23. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134(2): 136-51.
24. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345(7): 517-25.
25. Hunninghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc Am Thorac Soc 2007; 4(5): 449-52.
26. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3(4): 364-72.
27. Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Curr Med Chem 2009; 16(11): 1400-17.
28. Antoniou KM, Pataka A, Bouros D, Siafakas NM. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2007; 20(5): 453-61.
29. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010; 4(6): 367-88.
30. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97(1): 232-7.
31. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96(3): 319-28.
32. Gunther A, Lubke N, Ermert M, et al. Prevention of bleomycininduced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Cell Mol Biol 2003; 168(11): 1358-65.
33. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinaseactivated receptor-1 signaling affords protection from bleomycininduced lung inflammation and fibrosis. Am J Pathol 2005; 166(5): 1353-65.
34. Tager AM, Kradin RL, LaCamera P, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004; 31(4): 395-404.
35. Tager AM, Lacamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14(1): 45-54.
36. Oga T, Matsuoka T, Yao C, et al. Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 2009; 15(12): 1426-30.
37. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99(3): 301-12.
38. Argraves KM, Gazzolo PJ, Groh EM, et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem 2008; 283(36): 25074-81.
39. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278(47): 47281-90.
40. Dudek SM, Camp SM, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 2007; 19(8): 1754-64.
41. Camp SM, Bittman R, Chiang ET, et al. Synthetic analogues of FTY720 differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 2009; 331: 54-64.
42. Tauseef M, Kini V, Knezevic N, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res 2008; 103(10): 1164-72.
43. Wadgaonkar R, Patel V, Grinkina N, et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol 2009; 296(4): L603-13.
44. Camerer E, Regard JB, Cornelissen I, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 2009; 119(7): 1871-9.
45. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2006; 2(8): 434-41.
46. Peng X, Hassoun PM, Sammani S, et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004; 169(11): 1245-51.
47. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004; 170(9): 987-93.
48. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006; 290(6): F1516-24.
49. Okazaki M, Kreisel F, Richardson SB, et al. Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. Am J Transplant 2007; 7(4): 751-8.
50. Szczepaniak WS, Zhang Y, Hagerty S, et al. Sphingosine 1-phosphate rescues canine LPS-induced acute lung injury and alters systemic inflammatory cytokine production in vivo. Transl Res 2008; 152(5): 213-24.
51. Liu HB, Cui NQ, Wang Q, Li DH, Xue XP. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. Pancreas 2008; 36(3): e10-5.
52. Martin P. Wound healing--aiming for perfect skin regeneration. Science 1997; 276(5309): 75-81.
53. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341(10): 738-46.
54. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 2001; 56(12): 916-23.
55. McKeown S, Richter AG, O'Kane C, McAuley DF, Thickett DR. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J 2009; 33(1): 77-84.
56. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96(3): 1621-30.
57. Olman MA, Simmons WL, Pollman DJ, et al. Polymerization of fibrinogen in murine bleomycin-induced lung injury. Am J Physiol 1996; 271(4 Pt 1): L519-26.
58. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156(2 Pt 1): 631-6.
59. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106(11): 1341-50.
60. Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159(4): 1383-95.
61. Scotton CJ, Krupiczojc MA, Konigshoff M, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119(9): 2550-63.
62. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31(4 Suppl): S213-20.
63. Chambers RC, Laurent GJ. Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans 2002; 30(2): 194-200.
64. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Nat Acad Sci USA 2006; 103(35): 13180-5.
65. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000; 106(12): 3.
66. Ploplis VA, Wilberding J, McLennan L, et al. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol 2000; 157(3): 703-8.
67. Jenkins RG, Su X, Su G, et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006; 116(6): 1606-14.
68. Sanchez T, Thangada S, Wu MT, et al. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci USA 2005; 102(12): 4312-7.
69. Long JS, Natarajan V, Tigyi G, Pyne S, Pyne NJ. The functional PDGFbeta receptor-S1P1 receptor signaling complex is involved in regulating migration of mouse embryonic fibroblasts in response to platelet derived growth factor. Prostaglandins Other Lipid Mediat 2006; 80(1-2): 74-80.
70. Hashimoto M, Wang X, Mao L, et al. Sphingosine 1-phosphate potentiates human lung fibroblast chemotaxis through the S1P2 receptor. Am J Respir Cell Mol Biol 2008; 39(3): 356-63.
71. Donati C, Cencetti F, Nincheri P, et al. Sphingosine 1-phosphate mediates proliferation and survival of mesoangioblasts. Stem Cells 2007; 25(7): 1713-9.
72. Schnitzer SE, Weigert A, Zhou J, Brune B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res 2009; 7(3): 393-401.
73. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3(4): 350-6.
74. Kono Y, Nishiuma T, Nishimura Y, et al. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Respir Cell Mol Biol 2007; 37(4): 395-404.
75. Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA. Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res 2009; 82(2): 303-12.
76. Dhami R, He X, Schuchman EH. Acid sphingomyelinase deficiency attenuates bleomycin-induced lung inflammation and fibrosis in mice. Cell Physiol Biochem 2010; 26(4-5): 749-60.
77. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008; 34(1): 115-43; vii.
78. Radeke HH, von Wenckstern H, Stoidtner K, Sauer B, Hammer S, Kleuser B. Overlapping signaling pathways of sphingosine 1-phosphate and TGF-beta in the murine Langerhans cell line XS52. J Immunol 2005; 174(5): 2778-86.
79. Xin C, Ren S, Kleuser B, et al. Sphingosine 1-phosphate crossactivates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 2004; 279(34): 35255-62.
80. Sauer B, Vogler R, von Wenckstern H, et al. Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes. J Biol Chem 2004; 279(37): 38471-9.
81. Bu S, Kapanadze B, Hsu T, Trojanowska M. Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on transforming growth factor-beta/Smad signaling are mediated through the PTEN/PPM1A-dependent pathway. J Biol Chem 2008; 283(28): 19593-602.
82. Pattanaik D, Postlethwaite AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med 2010; 10(51): 161-7.
83. White ES, Atrasz RG, Hu B, et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006; 173(1): 112-21.
84. Ikeda H, Watanabe N, Ishii I, et al. Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. J Lipid Res 2009; 50(3): 556-64.
85. Davaille J, Gallois C, Habib A, et al. Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem 2000; 275(44): 34628-33.
86. Davaille J, Li L, Mallat A, Lotersztajn S. Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem 2002; 277(40): 37323-30.
87. Li C, Zheng S, You H, et al. Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol 2010; 54(6): 1205-13.
88. Liu X, Yue S, Li C, Yang L, You H, Li L. Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation. J Cell Physiol 2011; 226(9): 2370-7.
89. Jones BE, Lo CR, Srinivasan A, Valentino KL, Czaja MJ. Ceramide induces caspase-independent apoptosis in rat hepatocytes sensitized by inhibition of RNA synthesis. Hepatology 1999; 30(1): 215-22.
90. Tsugane K, Tamiya-Koizumi K, Nagino M, Nimura Y, Yoshida S. A possible role of nuclear ceramide and sphingosine in hepatocyte apoptosis in rat liver. J Hepatol 1999; 31(1): 8-17.
91. Lang PA, Schenck M, Nicolay JP, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13(2): 164-70.
92. Moles A, Tarrats N, Morales A, et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol 2010; 177(3): 1214-24.
93. Caballero S, Swaney J, Moreno K, et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and subretinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res 2009; 88(3): 367-77.